{"transactions":[{"id":4639748,"issuer":{"id":3758,"kind":"organization","name":"MiniMed Group, Inc.","symbol":"MMED"},"owners":[{"id":32006,"kind":"person","name":"Endicott David J.","position":1,"cik":"0001532133","reported_name":"Endicott David J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-13T22:10:33.000Z","date":"2026-10-09","kind":"grant","planned":false,"acquired":true,"shares":11795,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\") pursuant to the 2026 MiniMed Group, Inc. Long Term Incentive Plan that vest on the one-year anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares of common stock to be issued in connection with the vesting of one or more RSUs."}],"balance_after":11795,"source":{"system":"sec-edgar","filing":"0001532133-26-000004","document":"wk-form4_1791929430.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2062583/000153213326000004/wk-form4_1791929430.xml","form_type":"4"}},{"id":4255098,"issuer":{"id":157016,"kind":"organization","name":"Orexigen Therapeutics, Inc.","symbol":"OREXQ"},"owners":[{"id":32006,"kind":"person","name":"Endicott David J.","position":1,"cik":"0001532133","reported_name":"Endicott David J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-07-18T19:30:36.000Z","date":"2017-07-14","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the original number of shares of stock subject to the option (rounded down to the next whole number of shares) shall vest in equal monthly installments over 12 months following the vesting commencement date of July 14, 2017, subject to the Reporting Person's continuing service on the Issuer's Board of Directors through each such date, and subject to the terms of the Stock Option Agreement in the event of a change in control of the Issuer."}],"balance_after":5000,"derivative":{"exercise_price":2.88,"expiration_date":"2027-07-13","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-17-045598","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1382911/000120919117045598/doc4.xml","form_type":"4"}},{"id":4342002,"issuer":{"id":176636,"kind":"organization","name":"Zeltiq Aesthetics Inc","symbol":"ZLTQ"},"owners":[{"id":32006,"kind":"person","name":"Endicott David J.","position":1,"cik":"0001532133","reported_name":"Endicott David J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-04-28T13:18:24.000Z","date":"2017-04-28","kind":"other","acquired":false,"shares":16132,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly owned subsidiary of Allergan plc (\"Allergan\"), Blizzard Merger Sub, Inc. (\"Merger Sub\"), and the Issuer (the \"Merger Agreement\"), as approved by the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the \"Merger\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the terms of the Merger Agreement, out of the total of 16,132 shares held by the Reporting Person, (i) 8,477 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes, and (ii) 7,655 shares, representing unvested restricted stock units, were converted into a corresponding award of restricted stock units with respect to ordinary shares of Allergan, on the same terms and conditions as were applicable under such restricted stock units, as adjusted based on an exchange ratio."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly owned subsidiary of Allergan plc (\"Allergan\"), Blizzard Merger Sub, Inc. (\"Merger Sub\"), and the Issuer (the \"Merger Agreement\"), as approved by the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, out of the total of 16,132 shares held by the Reporting Person, (i) 8,477 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes, and (ii) 7,655 shares, representing unvested restricted stock units, were converted into a corresponding award of restricted stock units with respect to ordinary shares of Allergan, on the same terms and conditions as were applicable under such restricted stock units, as adjusted based on an exchange ratio."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-17-028602","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1415336/000120919117028602/doc4.xml","form_type":"4"}}]}